Merck (MRK), the New Jersey pharmaceutical giant behind blockbuster oncology drug Keytruda and a broad vaccine and animal health portfolio, is facing a congressional inquiry into its clinical trial operations in China, a development that lands just as the stock trades near the top of its 52 week range at 128.50 dollars.
At a Glance
- MRK trades at 128.50 USD, down 0.68% on the day, within a 52 week span of 107.90 to 130.29
- Market capitalization stands at 317.77 billion dollars with a trailing P/E of 35.99
- Dividend yield sits at 2.65%, and RSI reads 68.01, approaching overbought territory
- House Select Committee on China has demanded records on 224 Merck clinical studies in China since 2005
- AbbVie faces a parallel inquiry covering more than 100 studies since 2007
| Price | 128.5 USD |
|---|---|
| Day change | -0.88 (-0.68%) |
| 52-week range | 107.9 – 130.29 |
| Market cap | $317.77B |
| P/E ratio | 35.99 |
| EPS (ttm) | 3.57 |
| Dividend yield | 2.65% |
| RSI (14) | 68.01 |
| Volume | 11,837,218 |
A Bipartisan Probe Into Clinical Trial Sites
A bipartisan group of lawmakers has opened national security investigations into Merck and AbbVie (ABBV), focusing on clinical trials conducted at Chinese facilities, some tied directly to the country's military apparatus. Rep. John Moolenaar, the Michigan Republican who chairs the House Select Committee on China, signed letters dated Monday that give both drugmakers until July 17 to detail how they select trial locations, safeguard patient data, and enforce safety protocols. The letters single out sites in Xinjiang and hospitals connected to the People's Liberation Army for particular scrutiny.
Committee findings trace Merck's involvement back to 2005, tallying 224 clinical studies conducted in China. Of those, at least 31 took place in Xinjiang and 40 occurred at facilities with military ties. AbbVie's footprint since 2007 spans more than 100 studies, including at least 17 in Xinjiang and 16 at military linked centers. The letters, addressed to Merck CEO Robert Davis and AbbVie CEO Robert Michael, stop short of accusing either company of breaking any law. They instead frame the concern around intellectual property exposure and ethical risk, arguing that research conducted inside PRC military hospitals could expose sensitive biotechnology know how to transfer toward Chinese military applications.
Lawmakers also invoked Xinjiang's status as the site of what the letters describe as genocide against Uyghurs and other minority groups, and pointed to documented lapses by Chinese researchers in securing informed consent from trial participants. Merck responded that patient safety and ethical conduct remain central to its clinical research program and that it adheres to global regulatory guidelines. China's embassy in Washington dismissed the committee's action, calling it lacking in credibility and accusing Washington of politicizing trade and technology matters.
The Bigger Biotech Rivalry With China
The scrutiny of Merck and AbbVie fits into a wider Washington concern about China's expanding footprint in drug development. Data cited alongside the Reuters report shows China's share of global early stage drug development rose from 8% in 2015 to over 32% by 2024, while the American share fell from 48% to roughly 37% across the same stretch. That shift has sharpened bipartisan anxiety in Congress about where cutting edge biotech research physically happens and who ultimately controls the resulting intellectual property.
AbbVie, which has leaned on newer immunology drugs Skyrizi and Rinvoq to offset declining Humira sales as biosimilar competitors erode that franchise, declined to comment directly on the investigation. The Biosecure Act, signed into law last year under President Trump, already restricts federal agencies from doing business with certain non-U.S. biotechnology firms, a signal that the regulatory environment around China linked biotech activity is tightening well beyond this single congressional letter.
What the Numbers Say
Merck's valuation, momentum, and income profile each tell a slightly different story right now. On valuation, a trailing P/E of 35.99 sits well above the pharmaceutical sector's historical norm, which typically runs in the mid teens to low twenties for large cap drugmakers with mature revenue bases. That multiple suggests the market is pricing in continued growth from Keytruda and the broader pipeline rather than treating Merck as a value name, even as the stock's proximity to its 52 week high of 130.29 shows investors have bid the shares up meaningfully from the 107.90 low.
Momentum readings reinforce that picture. An RSI of 68.01 sits just under the conventional overbought threshold of 70, indicating the stock has attracted sustained buying pressure without yet flashing a technical exhaustion signal. Combined with a daily decline of 0.68% to 128.50, the tape suggests a stock consolidating near highs rather than one in clear directional momentum either way. The 2.65% dividend yield offers income investors a moderate return relative to the broader market, though it trails the yields typically found among Merck's pharmaceutical peers that pair slower growth with heavier payout ratios.
The bull case rests on Merck's earnings durability: a market cap of 317.77 billion dollars reflects continued confidence in Keytruda's oncology dominance and the company's vaccine and animal health diversification, even as patent cliff concerns loom over the next several years. Bears point to the elevated P/E as a sign the stock has limited room for multiple expansion, and argue that any material findings from the congressional investigation, particularly around intellectual property exposure in China, could introduce headline risk that a richly valued stock is less equipped to absorb without a pullback.
Frequently Asked Questions
What exactly are lawmakers investigating at Merck?
The House Select Committee on China is examining Merck's clinical trial practices in China, including how the company selects trial sites, protects patient data, and manages safety standards, with particular focus on studies conducted in Xinjiang and at hospitals linked to the Chinese military.
Has Merck been accused of breaking any laws?
No. The committee's letters explicitly state that neither Merck nor AbbVie is known to have violated any law, though the lawmakers raise ethical and national security concerns about conducting research at military linked facilities.
How has Merck stock reacted to the news?
Merck shares were trading at 128.50 dollars, down 0.68% on the day the data was recorded, still within striking distance of the stock's 52 week high of 130.29.
What is the deadline for Merck to respond to the committee?
Merck and AbbVie have been asked to submit the requested information to the House Select Committee on China by July 17.
Where This Leaves Merck Investors
The congressional inquiry adds a layer of geopolitical risk to a stock already trading at a premium valuation relative to its own history and much of the pharmaceutical sector. Nothing in the committee's letters alleges wrongdoing, and Merck has publicly reaffirmed its commitment to ethical research standards, but the July 17 deadline sets a concrete date by which more detail, and potentially more market reaction, could emerge. For now, the stock's technical posture, elevated RSI, high P/E, and proximity to 52 week highs, suggests a market still willing to look past the headline risk in favor of Merck's underlying earnings power.
